Fennec Pharmaceuticals (FENC) Q2 FY26 earnings call

Fennec Pharmaceuticals delivered a strong second quarter, marked by record PEDMARC demand and significant commercial expansion, including a 78% year-over-year increase in net product sales. The company achieved positive adjusted EBITDA and saw substantial growth in healthcare provider engagement, driven by an expanded sales force and innovative disease awareness campaigns. Management expressed confidence in continued momentum through the second half of the year, while also actively exploring lifecycle management opportunities and international partnerships.